Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC.
Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC. Int J Oncol. 2020 10; 57(4):939-955.
View in:
PubMed
subject areas
Animals
Antineoplastic Combined Chemotherapy Protocols
Apoptosis
Carcinoma, Non-Small-Cell Lung
Cell Line, Tumor
Cell Proliferation
Cisplatin
DNA-Activated Protein Kinase
Drug Resistance, Neoplasm
Drug Synergism
ErbB Receptors
Female
Humans
Lung Neoplasms
Mice
Mice, Nude
Mutation
Proto-Oncogene Proteins p21(ras)
Xenograft Model Antitumor Assays
authors with profiles
Tao Pan